What is Onivyde and what is it used for?
Onivyde is an encapsulation of irinotecan hydrochloride, an established chemotherapy drug, within tiny lipid spheres called liposomes [1]. This novel delivery method is designed to improve how irinotecan is distributed in the body [1]. Onivyde is specifically indicated for patients with metastatic pancreatic cancer who have previously been treated with gemcitabine-based chemotherapy [1]. It is typically administered in combination with other chemotherapy agents, such as leucovorin and fluorouracil [1].
How does Onivyde work differently from standard irinotecan?
The liposomal encapsulation of Onivyde alters the drug's pharmacokinetic profile compared to conventional irinotecan hydrochloride [1]. This formulation allows for a different distribution and release of the active chemotherapy agent within the body, potentially leading to sustained exposure and a modified safety and efficacy profile [1].
What is the clinical data supporting Onivyde's use?
The approval of Onivyde was based on a clinical trial that demonstrated a survival benefit for patients treated with Onivyde in combination with leucovorin and fluorouracil compared to those treated with fluorouracil, leucovorin, and oxaliplatin [2]. This trial specifically enrolled patients with previously treated metastatic pancreatic adenocarcinoma [2].
When does Onivyde's patent protection expire?
Information regarding the specific patent expiry dates for Onivyde may be found on DrugPatentWatch.com [3]. Patent exclusivity for drugs plays a significant role in market dynamics and the potential for generic or biosimilar competition [3].
Who are the competitors for Onivyde in pancreatic cancer treatment?
The treatment landscape for metastatic pancreatic cancer is competitive, with various chemotherapy regimens and targeted therapies available [4]. Other drugs and combinations used in this setting include FOLFIRINOX (a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) and gemcitabine with nab-paclitaxel [4]. The choice of treatment often depends on the patient's prior therapies and overall health status [4].
What are the side effects associated with Onivyde?
Common side effects reported with Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [1]. Severe side effects can also occur and may require medical attention [1]. Patients should discuss potential side effects and their management with their healthcare provider [1].
What is the typical cost of Onivyde?
The cost of Onivyde can vary significantly based on factors such as insurance coverage, pharmacy, and dosage [5]. It is important for patients to consult with their healthcare provider and insurance provider to understand their out-of-pocket expenses [5].
Can generic versions of Onivyde become available?
The availability of generic versions of Onivyde depends on the expiration of its patent protection and any associated regulatory exclusivities [3]. Once these protections expire, other manufacturers may seek approval to market generic versions of the drug, which could potentially lower costs [3].
What are the risks for patients taking Onivyde?
Risks associated with Onivyde include the potential for severe or life-threatening diarrhea, which can lead to dehydration and electrolyte imbalances [1]. Neutropenia, a decrease in white blood cells, is also a concern, increasing the risk of infection [1]. Patients should be closely monitored by their healthcare team during treatment [1].
What is the mechanism of action for irinotecan, the active component of Onivyde?
Irinotecan is a topoisomerase I inhibitor [1]. Topoisomerase I is an enzyme essential for DNA replication and transcription. By inhibiting this enzyme, irinotecan causes DNA damage, leading to the death of cancer cells [1]. The liposomal formulation aims to prolong the circulation time of irinotecan and deliver it more effectively to tumor sites [1].
---
Sources:
[1] https://www.onivyde.com/
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-onivyde-irinotecan-liposome-injection-combination-metastatic-adenocarcinoma-pancreas
[3] https://drugpatentwatch.com/
[4] https://www.cancer.org/cancer/types/pancreatic-cancer/treatment/chemotherapy.html
[5] https://www.goodrx.com/onivyde